Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

December 31, 2011

Conditions
Neoplasms, Breast
Interventions
DRUG

lapatinib

Oral administration

DRUG

Pazopanib

Oral administration

Trial Locations (126)

112

GSK Investigational Site, Taipei

333

GSK Investigational Site, Tao-Yuan County

500

GSK Investigational Site, Changhua

1000

GSK Investigational Site, Brussels

GSK Investigational Site, Manila

1008

GSK Investigational Site, Sampaloc Manila

1090

GSK Investigational Site, Jette

1101

GSK Investigational Site, Quezon City

2080

GSK Investigational Site, Ariana, Tunis

2610

GSK Investigational Site, Wilrijk

2650

GSK Investigational Site, Edegem

3000

GSK Investigational Site, Sfax

4000

GSK Investigational Site, Sousse

4074

GSK Investigational Site, Scarborough

6000

GSK Investigational Site, Perth

GSK Investigational Site, Cebu

10330

GSK Investigational Site, Bangkok

10367

GSK Investigational Site, Berlin

11796

GSK Investigational Site, Cairo

12163

GSK Investigational Site, Berlin

13273

GSK Investigational Site, Marseille Cedex BP 156

19111

GSK Investigational Site, Philadelphia

20010

GSK Investigational Site, Washington D.C.

20141

GSK Investigational Site, Milan

25421

GSK Investigational Site, Pinneberg

27710

GSK Investigational Site, Durham

28033

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

29425

GSK Investigational Site, Charleston

33076

GSK Investigational Site, Bordeaux

34390

GSK Investigational Site, Istanbul

37044

GSK Investigational Site, Tours

38138

GSK Investigational Site, Memphis

40000

GSK Investigational Site, Khon Kaen

41013

GSK Investigational Site, Seville

42551

GSK Investigational Site, Velbert

44623

GSK Investigational Site, Herne

44805

GSK Investigational Site, Saint-Herblain

45122

GSK Investigational Site, Essen

46009

GSK Investigational Site, Valencia

46010

GSK Investigational Site, Valencia

47166

GSK Investigational Site, Duisburg

48201

GSK Investigational Site, Detroit

49100

GSK Investigational Site, Petah Tikva

52000

GSK Investigational Site, Lampang

52621

GSK Investigational Site, Ramat Gan

53400

GSK Investigational Site, Lahore

53840

GSK Investigational Site, Troisdorf

54600

GSK Investigational Site, Lahore

55131

GSK Investigational Site, Mainz

58452

GSK Investigational Site, Witten

59020

GSK Investigational Site, Lille

59100

GSK Investigational Site, Prato (PO)

59322

GSK Investigational Site, Valenciennes

60000

GSK Investigational Site, Multan

60099

GSK Investigational Site, Zion

60596

GSK Investigational Site, Frankfurt am Main

60637

GSK Investigational Site, Chicago

63011

GSK Investigational Site, Clermont-Ferrand

63739

GSK Investigational Site, Aschaffenburg

64100

GSK Investigational Site, Bayonne

65000

GSK Investigational Site, Phitsanulok

68070

GSK Investigational Site, Mulhouse

68114

GSK Investigational Site, Omaha

68161

GSK Investigational Site, Mannheim

69008

GSK Investigational Site, Lyon

70300

GSK Investigational Site, Zrifin

75248

GSK Investigational Site, Paris

75970

GSK Investigational Site, Paris

76100

GSK Investigational Site, Rehovot

77030

GSK Investigational Site, Houston

80205

GSK Investigational Site, Denver

80637

GSK Investigational Site, Munich

83022

GSK Investigational Site, Rosenheim

84403

GSK Investigational Site, Ogden

89075

GSK Investigational Site, Ulm

90806

GSK Investigational Site, Long Beach

92210

GSK Investigational Site, Saint-Cloud

95816

GSK Investigational Site, Sacramento

98109

GSK Investigational Site, Seattle

100021

GSK Investigational Site, Beijing

100071

GSK Investigational Site, Beijing

115478

GSK Investigational Site, Moscow

169610

GSK Investigational Site, Singapore

197022

GSK Investigational Site, Saint Petersburg

197758

GSK Investigational Site, Saint Petersburg

200032

GSK Investigational Site, Shanghai

300060

GSK Investigational Site, Tianjin

390011

GSK Investigational Site, Ryazan

400015

GSK Investigational Site, Cluj-Napoca

420111

GSK Investigational Site, Kazan'

454087

GSK Investigational Site, Chelyabinsk

700106

GSK Investigational Site, Iași

7500921

GSK Investigational Site, Santiago

08043

GSK Investigational Site, Voorhees Township

H2L 4M1

GSK Investigational Site, Montreal

H4J 1C5

GSK Investigational Site, Montreal

481-0469

GSK Investigational Site, Temuco

254-0364

GSK Investigational Site, Viña del Mar

656 53

GSK Investigational Site, Brno

500 05

GSK Investigational Site, Hradec Králové

180 00

GSK Investigational Site, Prague

02999

GSK Investigational Site, Lohsa

08060

GSK Investigational Site, Zwickau

185 47

GSK Investigational Site, Athens

Unknown

GSK Investigational Site, Hong Kong

GSK Investigational Site, Sheung Wan

GSK Investigational Site, Tuenmen

GSK Investigational Site, Casablanca

GSK Investigational Site, Hassan Rabat

GSK Investigational Site, Rabat

GSK Investigational Site, Izmir

07100

GSK Investigational Site, Sassari

Lima 34

GSK Investigational Site, Lima

022328

GSK Investigational Site, Bucharest

400-711

GSK Investigational Site, Incheon

120-752

GSK Investigational Site, Seodaemun-gu, Seoul

138-736

GSK Investigational Site, Songpa-gu, Seoul

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

HA6 2RN

GSK Investigational Site, Northwood

CH63 4JY

GSK Investigational Site, Bebington, Wirral

SW3 6JJ

GSK Investigational Site, London

SM2 5PT

GSK Investigational Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00558103 - Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | Biotech Hunter | Biotech Hunter